Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT04577703 Completed - Clinical trials for Advanced Solid Tumors

First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors

Start date: February 8, 2014
Phase: Phase 1
Study type: Interventional

This is a phase I, single-arm, single-center, open-label, dose-escalation Study evaluating the safety and efficacy of CT053PTSA in patients with Advanced Solid Tumors

NCT ID: NCT04574947 Completed - Anesthesia Clinical Trials

Lidocaine And Neuromonitoring in Thyroid Surgery

Start date: January 25, 2021
Phase: Phase 4
Study type: Interventional

The aim of this study is to test the hypothesis that the quality of recovery with topical lidocaine is better than placebo.

NCT ID: NCT04560270 Completed - Pancreatic Cancer Clinical Trials

CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer

Start date: April 25, 2016
Phase: N/A
Study type: Interventional

With an incidence of more than 11,600 new cases per year in France and an annual number of deaths close to the incidence rate, adenocarcinoma of the pancreas is a public health problem. The aim of this study is to assess the predictive value of response to the 1st line of chemotherapy of mutated KRAS ctDNA (circulating tumor DNA) in unresectable metastatic or locally advanced pancreatic adenocarcinomas.

NCT ID: NCT04557540 Completed - Clinical trials for Obesity-Related Malignant Neoplasm

Weight Loss Interventions for Black Adults of Faith

Start date: September 25, 2021
Phase: N/A
Study type: Interventional

This trial compares the effect of intermittent fasting versus continuous caloric reduction for the reduction of body weight in Black adults of faith. Intermittent fasting and continuous caloric reduction interventions may help Black adults of faith lose weight, improve their health, and help reduce cancer risk.

NCT ID: NCT04551963 Completed - B-cell Malignancies Clinical Trials

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

Start date: November 15, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of this study was to assess the steady-state zanubrutinib pharmacokinetics (PK) when co-administered with moderate and strong cytochrome P450 family 3 subfamily A (CYP3A) inhibitors.

NCT ID: NCT04549662 Completed - Surgery Clinical Trials

The HepatoPancreaticoBiliary Resection Arginine Immunomodulation (PRIMe) Trial

PRIMe
Start date: June 16, 2021
Phase: N/A
Study type: Interventional

This is a randomized controlled blinded superiority trial to evaluate the impact of perioperative immunosupplementation on immune function following resection for hepatopancreaticobiliary (HPB) malignancy.

NCT ID: NCT04547205 Completed - Solid Tumor Clinical Trials

A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors

Start date: June 6, 2020
Phase: Phase 1
Study type: Interventional

This is a first in human(FIH) study to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity and anti-tumor activity of AK109, an anti-VEGFR2 monoclonal antibody, as a single agent in adult subjects with advanced solid tumor.

NCT ID: NCT04538599 Completed - Clinical trials for Hematologic Malignancies

RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies

Start date: September 10, 2020
Phase: Phase 1
Study type: Interventional

This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T/NK-cell hematologic malignancies. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.

NCT ID: NCT04537715 Completed - Solid Tumor Clinical Trials

Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer

Start date: April 23, 2020
Phase: Phase 1
Study type: Interventional

The participants of this study will have advanced malignancies (also known as advanced cancer). The main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the tazemtostat (the study drug) when administered in combination with another drug. Part 1 of the study will evaluate the interaction between the drugs tazemetostat and itraconazole. Part 2 of the study will evaluate the interaction between the drugs tazemetostat and rifampin For both Parts 1 and 2, safety and the level that effects of the study drug can be tolerated (known as tolerability) will be assessed throughout.

NCT ID: NCT04524728 Completed - Neoplasm Malignant Clinical Trials

Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

Start date: December 2016
Phase:
Study type: Observational [Patient Registry]

This is a multicentre real-world experience aimed at verifying the outcome of palbociclib plus ET in an unselected population of MBC patients. The primary endpoint is the clinical benefit rate (CBR); secondary aims are the median PFS (mPFS), overall survival (OS) and safety.